Nath Bio-Genes (India) Ltd (NATHBIOGEN) is currently trading at 153.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Nath Bio-Genes (India) Limited develops, produces, processes and markets hybrid and GM seeds across field crops and vegetables, and sells plant nutrient supplements; it operates ten processing plants, cold-storage and conditioning facilities, multiple R&D stations and a pan-India distribution network of approximately 20,000 distributors and dealers spanning 23 states. Recent financial momentum shows a strong top-line rebound with Q3FY26 revenue at ₹660 million (79% YoY) and 9MFY26 revenue of ₹3,859 million (23% YoY), while gross profit and PAT expanded year-on-year; however the company reported compressed EBITDA margins in Q3 and mixed margin signals across nine months, requiring scrutiny of cost and mix drivers. R&D and product differentiation are core to Nath Bio-Genes’ strategy: a DSIR-recognised R&D setup, 18 breeding and evaluation stations, extensive multi-location trial processes and a germplasm collection have driven successful seed launches such as Sanket and Daksh, which are reported to rank top-three in several geographies under diverse planting conditions. The company is actively de-risking and diversifying beyond cotton by accelerating growth in paddy, maize and vegetable seeds; FY26 nine-month volumes show maize up ~95% and vegetable seeds up ~43% YoY, supported by new product introductions and expansion into international markets via a Uzbekistan JV, pointing to multiple growth drivers under development. Balance-sheet metrics reflect improving leverage and liquidity: net debt reduced to ₹235 million in FY25 while net worth stands at ₹6,487 million, but elevated inventories (₹3,307 million in FY25) and higher finance costs signal working-capital intensity and the need to manage seasonality and operating cash conversion.

Over the past 52 weeks, Nath Bio-Genes (India) Ltd has traded between a low of ₹126.75 and a high of ₹207.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Nath Bio-Genes (India) Ltd has a market capitalization of approximately 292.66. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Nath Bio-Genes (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 7.57 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 292.66 Cr, Nath Bio-Genes (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Nath Bio-Genes (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Nath Bio-Genes (India) Ltd is 7.57. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The BSE scrip code is 537291 and the NSE symbol is NATHBIOGEN, as disclosed in the corporate information section.

The company said its Board of Directors will meet on July 29, 2026 to consider and approve the unaudited Q1 FY27 financial results.

The company disclosed that its Board of Directors will meet on January 31, 2026 for quarterly results.